

Remarks/Arguments

This paper is being filed responsive to an "Office Communication" mailed from the U.S. Patent and Trademark Office on 28 November 2005 which was never received by the undersigned attorney. Further, a Notice of Abandonment was mailed from the USPTO on 18 August 2006 and a Request for Withdrawal of Notice of Abandonment was filed. The "Office Communication" was remailed from the USPTO on 1 December 2006.

In response to the "Office Communication", the Examiner has stated that Applicant is required to make an election for each of the groups of Species A, B, C and D.

In the first Response to Restriction Requirement, Applicant apparently misunderstood the Examiner's direction and chose Species D directed to a detecting method.

For Species D, Applicant elects the detection by its quartz crystal microbalance (QCM) with a flow injection system.

For Species B, Applicant elects the organic compound being a derivative of cystine.

For Species A, Applicant elects the monomer N-benzylacrylamide in Claim 5.

For Species C, Applicant elects the template molecule peptide.

MR957-1411

Appln. No. 10/690,600

Reply to Office Action dated 11/28/2005

With regard to the monomers in Claim 10, Applicant submits that this is a mixture and one monomer cannot be elected.

It is believed that Claims 1-11 read on the elected Species and Sub-Species as required by the Examiner.

In the event there are any charges associated with the filing of this Response to the "Office Communication", the Honorable Director of Patents and Trademarks is hereby authorized to charge Deposit Account 18-2011 for such charges.

Respectfully submitted,
FOR: ROSENBERG, KLEIN & LEE

A handwritten signature in cursive script, appearing to read "Morton J. Rosenberg", with a long horizontal flourish extending to the right.

Morton J. Rosenberg
Registration No. 26,049

Dated: 12/15/2006

Suite 101
3458 Ellicott Center Drive
Ellicott City, MD 21043
Tel: 410-465-6678
Customer No. 04586